Benign neoplasm: Lacrimal gland and duct

CD2_BENIGN_LACRIMAL

choriocarcinoma: An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.

Endpoint definition

FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D31.5&
Hospital discharge: ICD-9 2247
Cause of death: ICD-10 D31.5&
Cause of death: ICD-9 2247

2 out of 7 registries used, show all original rules.

30

diagram downward connector

Check minimum number of events None

30

diagram downward connector

Include endpoints None

30

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

29

diagram downward connector
CD2_BENIGN_LACRIMAL

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D31
Name in latin Neoplasma benignum glandulae lacrimalis

Similar endpoints

Summary Statistics

Key figures

All Female Male
Number of individuals 29 23 6
Unadjusted prevalence (%) 0.01 0.01 0.00
Mean age at first event (years) 58.76 59.24 56.90

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_BENIGN_LACRIMAL – Benign neoplasm: Lacrimal gland and duct
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Benign neoplasm: Lacrimal gland and duct

Endpoint not on priority list, no data to show.